Research Paper Volume 12, Issue 11 pp 11025—11041

LncRNA ADAMTS9-AS2 inhibits gastric cancer (GC) development and sensitizes chemoresistant GC cells to cisplatin by regulating miR-223-3p/NLRP3 axis

class="figure-viewer-img"

Figure 1. The expression status of LncRNA ADAMTS9-AS2 and miR-223-3p in GC clinical specimens and cell lines. Real-Time qPCR was used to examine the levels of (A) LncRNA ADAMTS9-AS2 and (B) miR-223-3p in cancer tissues and adjacent normal tissues collected from GC patients. (C) Pearson correlation analysis was conducted to analyze the correlation of LncRNA ADAMTS9-AS2 and miR-223-3p in GC tissues. (D) Pan-cancer analysis was performed to analyze the correlation of LncRNA ADAMTS9-AS2 and miR-223-3p for 372 specimens from the patients with stomach adenocarcinoma (STAD). (E, F) Kaplan-Meier survival analysis was performed to determine prognosis of GC patients with differential LncRNA ADAMTS9-AS2 and miR-223-3p expressions. Real-Time qPCR was used to measure the levels of (G) LncRNA ADAMTS9-AS2 and (H) miR-223-3p in GES-1 cells and GC cells. Each experiment repeated at least 3 times. **P < 0.01.